Measurement of prostate specific antigen complexed to α1- antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL

International Journal of Urology

Volumn 12, Issue 8, 2005, Pages 721-727

  Nakano, Yojiro ^a   Okamura, Kikuo ^b   Takamura, Shinichi ^c   Okamoto, Noriko ^d   Narishima, Masahiro ^e   Yoshino, Yasushi ^f   Hattori, Ryohei ^f   Ono, Yoshinari ^f   Ohshima, Shinichi ^b   Nagasaka, Tetsuro ^f  

^a TOSEI GENERAL HOSPITAL   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c Kosei Rengo Kainan Hospital   (Japan)

^d Kariya General Hospital   (Japan)

^e Meitetsu Hospital   (Japan)

^f NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Logistic regression analysis; Prostate cancer; PSA ACT; Relative probability for prostate cancer

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC;

AGED; ALPHA 1-ANTICHYMOTRYPSIN; BIOPSY; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UNNECESSARY PROCEDURES;

EID: 28544441048     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01167.x     Document Type: Article

References (21)

1. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol 1991; 145: 907-23.
2. Partin AW, Kattan MW, Subong ENP et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997; 277: 1445-51.
3. Egawa S, Suyama K, Arai Y et al. A study of pretreatment nomograms to predict pathological stage and biochemical recurrence after radical prostatectomy for clinically resectable prostate cancer in Japanese men. Jpn J. Clin. Oncol. 2001; 31: 74-81.
4. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate specific antigen in a community-based population of healthy man: establishment of age specific reference ranges. JAMA 1993; 270: 860-4.
5. Catalona WJ, Southwick PC, Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-60.
6. Benson MC, Whang IS, Olsson CA et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol. 1992; 147: 817-21.
7. Kalish J, Cooner WH, Graham SD Jr. Serum PSA adjusted for Volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland Volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994; 43: 601-6.
8. Maeda H, Arai Y, Ishitoya S, Okubo K, Aoki Y, Okada T. Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. J. Urol. 1997; 158: 2193-6.
9. Kikuchi E, Nakashima J, Ishibashi M et al. Prostate specific antigen adjusted for transition zone volume. The most powerful method for detecting prostate carcinoma. Cancer 2000; 89: 842-9.
10. Djavan B, Remzi M, Zlotta AR et al. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction. Tech. Urol. 1999; 5: 71-6.
11. Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20.
12. Kuriyama M, Kawada Y, Arai Y et al. Significance of free to total PSA ratio in men with slightly elevated serum PSA levels: a cooperative study. Jpn J. Clin. Oncol. 1998; 28: 661-5.
13. Vessella RL, Lange PH, Partin AW et al. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total assays. Urology 2000; 55: 909-14.
14. Okamura K, Takaba H, Kamihira O et al. Determination of the relative probability of prostate cancer to avoid unnecessary biopsy: a new concept. Int. J. Urol. 2005; 12: 345-52.
15. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991; 51: 222-6.
16. Stamey TA. Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2,1994. Urology 1995; 45: 173-84.
17. Maeda H, Arai Y, Aoki Y, Okubo K, Okada T, Maekawa S. Complexed prostate-specific antigen and its Volume indexes in detection of prostate cancer. Urology 1999; 54: 225-8.
18. Piironen T, Pettersson K, Suonpää M et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to α1-antichymotrypsin in blood samples. Urology 1996; 48: 81-7.
19. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
20. Saika T, Tsushima T, Nasu Y et al. Prostate specific antigen complexed to α1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer 2002; 94: 1685-91.
21. Kuriyama M, Uno H, Watanabe H et al. Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J. Clin. Oncol. 1999; 29: 617-22.